TransMedics is facing allegations of fraud, organ trafficking, and unethical practices that have triggered shareholder ...

TransMedics' stock remains under pressure after a weak third quarter, reduced Q4 guidance, the exit of the company's CFO, and ...

LOS ANGELES, CA / ACCESS Newswire / January 16, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is ...

TransMedics Gr TMDX has outperformed the market over the past 5 years by 12.34% on an annualized basis producing an average ...

JP Morgan has recently reduced TransMedics Group Inc (TMDX) stock to Neutral rating, as announced on December 17, 2024, according to Finviz. Earlier, on November 22, 2024, Needham had reduced the ...

NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today ...

In this video, I will talk about TransMedics (NASDAQ: TMDX) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.

TransMedics has previously touted its OCS as "the only FDA approved, portable, multi-organ, warm perfusion technology platform" and its NOP as providing a more efficient organ procurement process.

TransMedics is a commercial-stage medical technology company working on organ transplant therapy. Check out more about the ...

Shares of Transmedics (NASDAQ: TMDX) fell 28.1% in December, according to data from S&P Global Market Intelligence. On Dec. 2 ...